Compare Boeing Co (BA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Medpace Holdings Inc — how do they compare? Boeing Co trades at $218.21 (market cap $171.15B), while Medpace Holdings Inc trades at $536.12 (market cap $15.31B). The key difference: Boeing Co is far larger — about 11.2× Medpace Holdings Inc's market cap, and Boeing Co pays a 0.03% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| BA | MEDP | |
|---|---|---|
Market Cap | $171.15B | $15.31B |
Volume | 7,591,579 | — |
Sector | Industrials | Technology |
52-Week High | $252.15 | $620.59 |
52-Week Low | $179.12 | $308.88 |
Enterprise Value | $197.46B | $14.78B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $215.51, down 3.05% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 85.18 but improving revenue and net income, reaching $89.46B and $2.24B in 2025, respectively. Recent news highlights potential order wins, including discussions with Riyadh Air for additional 787s, while technical indicators point to support near $209.
Outlook remains cautiously optimistic with a consensus price target of $268.33, implying 24.5% upside, but risks include volatile cash flows, high debt, and ongoing operational challenges. Analyst sentiment is bullish with 66.7% buy ratings, though investors should monitor execution on delivery targets and margin improvements.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
